
About Cellulera Pharma Private Limited
Data last updated:
Cellulera Pharma Private Limited is a private limited company based in Bangalore, Karnataka, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 05 May 2017 and has been in existence for over 9 years.
The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN U74999KA2017PTC102836. The company has 1 GST registration on record, which is no longer active.
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Prasanna Shastry Kammaradi Srinivasa Shastry and Sridevi Sidambaram.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at No.130 Best County – 2 M.S. Palya Near Sambram College Vidyaranyapura, Bangalore, Karnataka, India – 560097.
The company is associated with 1 brand: Cellulera.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website cellulera.in.
Company details
Contact details
Cellulera Pharma Private Limited's registered office is in Bangalore, Karnataka. Its website is cellulera.in. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressNo.130 Best County – 2 M.S. Palya Near Sambram College Vidyaranyapura, Bangalore, Karnataka, India – 560097
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Cellulera Pharma Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Cellulera Pharma operates one associated brand: Cellulera. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Offers IT hardware, software tools, and enterprise solutions to businesses worldwide. | cellulera.in |
Business activity
The main business activity of Cellulera Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Cellulera Pharma Private Limited, buy the company report.
Financials of Cellulera Pharma Private Limited
FY 2025 filings availableFinancial Statement Summary
| Metrics | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 | FY 2017-18 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | |||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | |||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 | FY 2017-18 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | |||||
| Net Profit Margin | |||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Cellulera Pharma Private Limited, buy the company report.
Board of directors of Cellulera Pharma Private Limited
Cellulera Pharma has 2 current directors and 5 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Prasanna Shastry Kammaradi Srinivasa Shastry | Director | 05 May 2017 | 9 Years 6 Months | Current |
| Sridevi Sidambaram Also directs: Enhancly Consultancy LLP, Opinion Bunch Research Private Limited | Director | 02 Dec 2022 | 3 Years 11 Months | Current |
Auditor
Cellulera Pharma Private Limited is audited by HARISH KARKAL & CO for the financial year 2019.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| HARISH KARKAL & CO | FY 2019 | 017309S |
Shareholding
The shareholding of Cellulera Pharma Private Limited is on record for FY 2019, split between promoters, domestic institutions, public shareholders and others.
| Shareholder category | FY 2019 |
|---|---|
| Promoters | |
| Domestic institutional investors (DII) | |
| Public | |
| Others |
To see the full shareholding pattern of Cellulera Pharma Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Cellulera Pharma Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Cellulera Pharma Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Cellulera Pharma has 1 GST registration on record, and it has been cancelled or is inactive. Only active GST numbers are listed on this page.
To see the full GST registrations and return filing status of Cellulera Pharma Private Limited, buy the company report.
Recent activity
Cellulera Pharma Private Limited has 7 board changes on record since 2017: 2 appointments and 5 cessations. The latest: Jayaprakash Naik Paramananda ceased to be Director on 02 Dec 2022.
Frequently asked questions
Cellulera Pharma is an active private limited company based in Bangalore, Karnataka, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 05 May 2017 (9+ years old) and is registered under CIN U74999KA2017PTC102836.
Cellulera Pharma has 2 current directors:
- Prasanna Shastry Kammaradi Srinivasa Shastry - Director
- Sridevi Sidambaram - Director
The latest financial statements of Cellulera Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2018 are in the company report.
No. Cellulera Pharma has 1 GST registration on record and it is cancelled or inactive.
The CIN (Corporate Identification Number) of Cellulera Pharma is U74999KA2017PTC102836. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Cellulera Pharma was incorporated on 05 May 2017, making it 9+ years old. It is registered with the Registrar of Companies, Bangalore.
Jayaprakash Naik Paramananda ceased to be Director on 02 Dec 2022. Meer Jazeer Hussain ceased to be Director on 02 Dec 2022. Sridevi Sidambaram was appointed as Director on 02 Dec 2022. Cellulera Pharma has 7 board changes on record in total.
Cellulera Pharma can be reached through the website cellulera.in. Its registered office is in Bangalore, Karnataka, India.
The registered office of Cellulera Pharma is at No.130 Best County – 2 M.S. Palya Near Sambram College Vidyaranyapura, Bangalore, Karnataka, India – 560097.
Cellulera Pharma operates in the pharma industry, in the drug formulation and development segment.

